Ipilimumab (Yervoy; CAS 477202-00-9): NIOSH HD Category 1 FIFTY-FIRST Mechanism Class [FIRST CTLA-4 CHECKPOINT INHIBITOR EVER FDA APPROVED (BLA 125377; March 25, 2011; CTLA-4 KD ∼5 nM; IgG1 Kappa Fully Human; MW ∼148 kDa; Medarex UltiMAb; Cytotoxic T-Lymphocyte Antigen 4 Co-Inhibitory Receptor Blockade + T-Cell Priming Release + IgG1 Fc Intratumoral Treg ADCC Depletion)] + FIRST IMMUNE CHECKPOINT INHIBITOR EVER IN ONCOLOGY + Nobel Prize 2018 James P. Allison + Tasuku Honjo + MDX010-20 mOS 10.1 months vs 6.4 months (HR 0.66; First Survival Benefit Ever in Metastatic Melanoma) + 10-Year OS ∼20% (Durable Tail); BMS Co. Lawrenceville NJ Cority ÷10; BMS Biologics Devens MA VelocityEHS ÷10; Memorial Sloan Kettering New York NY EHS Insight ÷10; Glyphward Threshold 22; 617th Adversarial Attack; 139th Long-Form Blog

Ipilimumab (Yervoy®; CAS 477202-00-9; MW ∼148,000 Da; IgG1 kappa fully human monoclonal antibody; Medarex UltiMAb transgenic mouse technology; anti-CTLA-4 [CD152]; 448 aa heavy chain [×2] + 214 aa light chain [×2]; four disulfide bonds per heavy chain; intravenous 5 mg/mL histidine-sucrose-polysorbate 80 formulation; 50 mg/10 mL and 200 mg/40 mL single-use vials; NIOSH HD Category 1; BLA 125377; MECHANISM: FIFTY-FIRST MECHANISM CLASS in the 617-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — CTLA-4 (CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4) IMMUNE CHECKPOINT INHIBITORS; THE FIRST CTLA-4 CHECKPOINT INHIBITOR EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE; HISTORICAL PRECEDENCE: ipilimumab was approved March 25, 2011 — the first drug in history approved on the basis of immune checkpoint blockade; it preceded pembrolizumab (attack #618; FIFTY-SECOND class; BLA 125514 September 4, 2014) by 3.5 years and nivolumab (attack #619; BLA 125554 December 22, 2014) by 3.8 years; it opened an immunotherapy era that by 2026 encompasses >50 FDA approvals across >20 tumor types; Nobel Prize in Physiology or Medicine 2018 awarded jointly to James P. Allison PhD (UT MD Anderson Cancer Center) and Tasuku Honjo MD PhD (Kyoto University) “for their discovery of cancer therapy by inhibition of negative immune regulation”; CTLA-4 BIOLOGY: CTLA-4 (CD152) is an inhibitory co-receptor transiently upregulated on activated CD4+/CD8+ T cells and constitutively expressed at high density on immunosuppressive CD4+Foxp3+ regulatory T cells (Tregs); CTLA-4 competes with CD28 for CD80/CD86 (B7-1/B7-2) ligands on APCs with 10–100× higher affinity; CTLA-4:CD80/CD86 engagement recruits SHP-2 → Akt dephosphorylation → PI3K/IL-2 inhibition → T-cell anergy at the priming step in tumor-draining lymph nodes; DUAL MECHANISM: (1) T-cell priming checkpoint release (blocking CTLA-4:CD80/CD86 → CD28 co-stimulation unopposed → T-cell activation/priming); (2) IgG1 Fc ADCC/ADCP depletion of intratumoral Tregs (constitutive high CTLA-4 expression → opsonization by ipilimumab IgG1 → NK cell/macrophage ADCC → Treg depletion → Teff:Treg ratio increase); MDX010-20 PHASE 3: mOS 10.1 months vs 6.4 months (gp100 alone; HR 0.66; first OS benefit ever in metastatic melanoma); 10-year OS ∼20% (unprecedented durable tail); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 617th adversarial attack; 139th long-form blog).

FIFTY-FIRST MECHANISM CLASS: CTLA-4 Immune Checkpoint Inhibitors and the Opening of the Immunotherapy Era in Oncology

The fifty prior mechanism classes in the Glyphward adversarial portfolio trace the arc of small-molecule targeted oncology pharmacology: BCR-ABL tyrosine kinase (imatinib; Class 1; 2001), EGFR inhibitors across five generations (Classes 3/28/32/35/36), CDK4/6 (Class 33), BTK (Class 29), PARP1/2 (olaparib; Class 46; attack #605; 136th blog at glyphward.com), EZH2 histone methyltransferase (tazemetostat; Class 48; attack #612; 138th blog at glyphward.com), pan-HDAC (vorinostat; Class 47; attack #607; 137th blog at glyphward.com), NTRK/TRK (larotrectinib; Class 49; attack #613), and Menin-KMT2A PPI (revumenib; Class 50; attack #615). All fifty prior classes represent small-molecule kinase inhibitors, covalent warheads, zinc-chelation pharmacology, and protein-protein interaction blockers — each targeting an oncogenic enzyme, receptor, or scaffolding complex.

The FIFTY-FIRST mechanism class — ipilimumab and the CTLA-4 immune checkpoint inhibitors — introduces an entirely new pharmacological category: not a small molecule disrupting a tumor cell’s intrinsic signaling, but a therapeutic monoclonal antibody that reprograms the host immune system to recognize and destroy cancer. This is the FIRST IMMUNE CHECKPOINT THERAPY EVER, and it exploits a fundamental principle of adaptive immunity: that T-cell activation requires not only antigen recognition (Signal 1: TCR/MHC-peptide) but co-stimulatory signals (Signal 2: CD28:B7) and that co-inhibitory checkpoints (CTLA-4, PD-1, LAG-3) evolved to prevent autoimmunity by terminating T-cell responses after pathogen clearance. Cancer hijacks these same checkpoints to escape immune destruction. Blocking them restores anti-tumor T-cell activity without requiring knowledge of a specific oncogenic driver mutation — a paradigm fundamentally orthogonal to all fifty prior mechanism classes in this portfolio.

IMMUNE SYSTEM OVERVIEW RELEVANT TO CHECKPOINT BLOCKADE: The adaptive immune response requires CD8+ cytotoxic T lymphocytes (CTLs) to recognize peptide fragments of tumor-specific antigens (neoantigens from somatic mutations) presented by MHC class I molecules on tumor cells. The CTL recognition and activation sequence: (1) Immature dendritic cells in the tumor take up tumor debris, cross-present tumor peptides on MHC class I; mature DCs migrate to tumor-draining lymph nodes; (2) Naive CD8+ T cells (expressing TCR + CD28) encounter peptide/MHC-I on DCs; TCR:MHC-peptide engagement (Signal 1) + CD28:B7 co-stimulation (Signal 2) + cytokine signals (IL-12, IL-2) → full T-cell activation; (3) Activated T cells proliferate, differentiate into effector CTLs, traffic to tumor via CXCR3/CCR5 chemokine gradients; (4) In the tumor microenvironment (TME), CTLs recognize tumor cells and kill via perforin/granzyme + FasL; (5) CHECK POINTS LIMIT RESPONSES: CTLA-4 upregulation after activation competes with CD28, reducing priming; PD-1 upregulation on chronically stimulated effector CTLs in the TME, engaging PD-L1 on tumor cells, induces T-cell exhaustion; LAG-3 (CD223) co-inhibitory receptor further contributes to exhaustion. CHECKPOINT BLOCKADE: blocking these inhibitory receptors with therapeutic antibodies — ipilimumab for CTLA-4, pembrolizumab/nivolumab for PD-1, atezolizumab for PD-L1, relatlimab for LAG-3 — restores T-cell activity at different stages of the immune response cycle.

CTLA-4 Molecular Biology: Structure, Expression, Ligands, and Signaling Mechanism

CTLA-4 GENE AND PROTEIN: CTLA-4 (gene: CTLA4; chromosome 2q33.2; 223 aa; type I transmembrane protein) consists of: N-terminal signal peptide (1-35); extracellular IgV-like domain (36-161) with critical disulfide-bonded MYPPPY motif forming the ligand-binding face; single-pass transmembrane domain (162-182); short cytoplasmic tail (183-223) with two tyrosine-based inhibitory motifs (YVKM at Tyr201 and GVYVKM at Tyr218) and a serine-rich cluster. SURFACE EXPRESSION REGULATION: Naive CD4+/CD8+ T cells express negligible surface CTLA-4 (stored in intracellular vesicles); T-cell activation via TCR + CD28 → PI3K/Akt → transcriptional upregulation of CTLA4 mRNA (NFAT-dependent) + vesicle trafficking of CTLA-4 protein to cell surface; surface density peaks 48-72 h after activation → CTLA-4 out-competes CD28 → progressive dampening of the initial activation response (constitutive "off" switch mechanism); CONTRAST: CD4+Foxp3+ regulatory T cells (Tregs) constitutively express high surface CTLA-4 (continuous TCR stimulation by self-peptides in thymus during Treg development → constitutive CTLA4 expression); surface density on Tregs 10-100× higher than on activated effector T cells — this differential surface density is the key to ipilimumab’s Treg ADCC selectivity in the TME.

CTLA-4:B7 LIGAND INTERACTION: CD80 (B7-1; 288 aa; IgV+IgC extracellular domains; homodimer on APCs; higher affinity) and CD86 (B7-2; 329 aa; primarily IgV domain; monomer; lower affinity; kinetically faster on-rate). CTLA-4 binding: CTLA-4:CD80 KD ∼0.2 µM; CTLA-4:CD86 KD ∼0.3–2 µM; CD28:CD80 KD ∼4 µM; CD28:CD86 KD ∼20 µM; net CTLA-4 affinity advantage ∼10–100× over CD28 at physiological B7 densities on DCs. LIGAND STOICHIOMETRY AND TRANSENDOCYTOSIS: CTLA-4 also removes CD80/CD86 from APC surfaces by transendocytosis — CTLA-4 binds CD80/CD86 on APCs, the CTLA-4:B7 complex is internalized by the T cell (along with the APC membrane fragment), degraded in lysosomes — reducing B7 availability for CD28 co-stimulation; this transendocytosis function is constitutive on Tregs, contributing to APC maturation suppression in lymph nodes and the TME. CTLA-4 CYTOPLASMIC SIGNALING: CTLA-4 YVKM motif → SHP-2 phosphatase recruitment (binds YVKM pY) → PP2A (protein phosphatase 2A) association → dephosphorylation of Akt Thr308 → PI3K/Akt pathway inhibition → reduced IKK-β → NF-κB inhibition → reduced IL-2, IL-4 transcription; parallel: CTLA-4 engagement inhibits SH2-domain-containing 5′-inositol phosphatase (SHIP) → reduced PIP3 → reduced membrane recruitment of Akt; COMBINED: CTLA-4 signaling from either pathway produces T-cell anergy (unresponsiveness) or clonal deletion in lymph nodes, terminating the T-cell priming response against tumor antigens.

CTLA-4 KNOCKOUT PHENOTYPE: ctla4−/− mice develop fatal lymphoproliferative autoimmunity within 3–4 weeks of birth (massive T-cell expansion in multiple organs; fatal myocarditis/hepatitis/pancreatitis by postnatal day 25) confirming CTLA-4 is non-redundantly required for peripheral self-tolerance. This phenotype also explains why ipilimumab produces severe immune-related adverse events (irAEs) — it partially recapitulates the CTLA-4 knockout state systemically — and why irAE management requires high-dose immunosuppression (corticosteroids first-line; infliximab for steroid-refractory colitis; mycophenolate for steroid-refractory hepatitis). The irAE biology, CTLA-4 knockout precedent, and corticosteroid/biologic management algorithms are entirely absent from EHS OEL databases for CAS 477202-00-9.

Ipilimumab Molecular Pharmacology: IgG1 Kappa Structure, Medarex UltiMAb, CTLA-4 KD and the IgG1 Fc Treg ADCC Mechanism

IPILIMUMAB MOLECULAR STRUCTURE: Fully human IgG1 kappa monoclonal antibody (MW ∼148,000 Da; 4-chain Y-shaped structure: two identical heavy chains 448 aa [VH + CH1 + hinge + CH2 + CH3; 11 intrachain/interchain disulfide bonds total] + two identical light chains 214 aa [VL + CL; 2 disulfide bonds per chain]). IgG1 SUBCLASS PROPERTIES: half-life ∼21 days (FcRn-mediated recycling, pH-dependent; IgG1 FcRn affinity intermediate); passes human placenta via FcRn-mediated transplacental transport (relevant to H360 reproductive toxicity); complement activation (C1q binding to CH2–CH3 junction → classical complement cascade activation → CDC = complement-dependent cytotoxicity); FcγRI (CD64) high-affinity binding (KD ∼1–10 nM); FcγRIIa (CD32a) medium-affinity; FcγRIIIa (CD16a) medium affinity → ADCC (antibody-dependent cellular cytotoxicity) by NK cells via FcγRIIIa; FcγRIIIb on neutrophils; FcγRIIb (inhibitory) on B cells; these Fc interactions intact in IgG1 ipilimumab; CONTRAST WITH PD-1 INHIBITORS: pembrolizumab (IgG4 S228P) and nivolumab (IgG4) deliberately use IgG4 subclass which has: FcγRIIIa affinity >100-fold lower than IgG1; minimal ADCC; absent CDC; rationale — PD-1 is expressed on anti-tumor effector T cells; IgG4 prevents ADCC/ADCP elimination of the very T cells the drug is trying to rescue.

MEDAREX ULTIMAB TECHNOLOGY: Medarex Inc. (Princeton NJ; founded 1987 by Robert Bhatt and Donald Drakeman; acquired by Bristol-Myers Squibb 2009 for $2.4 billion) developed transgenic mice in which the endogenous murine immunoglobulin heavy chain (Igh) and kappa light chain (Igk) loci were replaced by unrearranged human VH-D-JH and Vκ-Jκ gene segments (with human Cγ1 constant regions); these UltiMAb mice undergo normal V(D)J recombination using human antibody gene segments → immunization with human antigen → fully human antibody sequences without any humanization steps; no humanization artifacts in CDRs; no residual murine sequences; IPILIMUMAB GENERATION: Medarex immunized UltiMAb mice with recombinant human CTLA-4 extracellular domain (Fc fusion protein); B cells from immunized mice were fused with murine myeloma cells or screened by phage display; selected hybridomas expressing high-affinity fully human IgG1 anti-CTLA-4; MDX-010 (ipilimumab) selected: KD ∼5 nM (Biacore SPR) for human CTLA-4 extracellular domain; does NOT cross-react with murine CTLA-4 (crucial: precludes mouse efficacy model validation; MDX-010 preclinical activity was assessed using surrogate anti-mouse CTLA-4 antibodies); does NOT bind CD28 (confirmed by SPR and cellular assays — no off-target co-stimulatory receptor activity); PHARMACOKINETICS: at 3 mg/kg IV q3w (approved melanoma dose): Cmax ∼132 µg/mL; AUC(0-∞) ∼3,984 µg·day/mL; t½ ∼14.7 days; volume of distribution ∼7.2 L; clearance ∼16.8 mL/day/kg; no cytochrome P450-mediated metabolism; elimination via catabolism in reticuloendothelial system; dose-proportional PK across 0.3–10 mg/kg; no drug-drug interactions via CYP system; concomitant corticosteroids (used for irAE management) do NOT reduce ipilimumab efficacy.

IgG1 FC TREG ADCC MECHANISM (IN DETAIL): The TME in metastatic melanoma contains abundant Foxp3+ Tregs that suppress anti-tumor T-cell responses: typical Teff:Treg ratios 1:1 to 3:1 in melanoma TME (vs. >10:1 in peripheral blood normal subjects). Intratumoral Tregs constitutively express high surface CTLA-4 density (measured by flow cytometry: mean fluorescence intensity 10–50× higher on Tregs vs. activated Teffs in the same TME). ADCC MECHANISM: ipilimumab IgG1 opsonizes CTLA-4-high Tregs; NK cells in the TME expressing FcγRIIIa (CD16a; V158 allele = higher affinity, F158 = lower affinity; germline polymorphism with functional consequences for anti-tumor mAb efficacy) bind ipilimumab Fc; NK cell FcγRIIIa crosslinking → intracellular calcium flux → ITAM signaling → NK cell activation → perforin/granzyme release → Treg lysis; macrophage FcγRIIIa/FcγRIIa also mediates ADCP (phagocytosis of opsonized Tregs); result: selective depletion of intratumoral Tregs → Teff:Treg ratio increase → augmented effector T-cell anti-tumor activity; CLINICAL EVIDENCE FOR TREG DEPLETION: tumor biopsies from responding ipilimumab patients (melanoma) show: Treg depletion in TME at week 5-12; increased Teff:Treg ratio correlating with tumor regression (Quezada et al., J Exp Med 2006; Simpson et al., JCI 2013); FUNCTIONAL IMPORTANCE: Fc-mutant ipilimumab (IgG1 N297A; Fc-null; ablated FcγR binding; retains CTLA-4 blocking but cannot deplete Tregs) showed inferior activity vs. wild-type ipilimumab IgG1 in humanized CTLA-4 knock-in mouse models — providing direct mechanistic evidence that IgG1 Fc function is not simply pharmacokinetic but is mechanistically required for full anti-tumor efficacy; this distinction is entirely absent from all EHS OEL platforms at CAS 477202-00-9.

Metastatic Melanoma Biology, Standard-of-Care History, and MDX010-20 Phase 3 Trial

MELANOMA EPIDEMIOLOGY AND STAGING: Melanoma arises from melanocytes (neural crest-derived pigment cells); incidence ∼100,000 new diagnoses/year in US (2024); 5th most common cancer in US men; metastatic (unresectable Stage III-IV): 5-year OS historically <15% before 2011; high somatic mutation burden (TMB; ultraviolet-signature C→T transitions; median ∼10–15 mut/Mb in cutaneous melanoma) → high neoantigen load → immunogenic → rationale for immunotherapy; BRAF V600E/K/other mutations: ∼40-50% of cutaneous melanoma; NRAS mutations: ∼20%; NF1 mutations: ∼15%; triple WT (wild-type BRAF/NRAS/NF1): ∼15%; PRIOR STANDARD-OF-CARE (pre-2011): dacarbazine (DTIC; DNA alkylating agent; FDA 1975): ORR ∼15–20%, no proven OS benefit over BSC; interleukin-2 (IL-2; high-dose IV bolus; FDA 1998): ORR ∼16%, CR ∼6% durable, but Grade 4 capillary leak/respiratory failure toxicity requiring ICU management; overall landscape: no drug had ever demonstrated an OS benefit in a randomized controlled trial for metastatic melanoma until ipilimumab; MDX010-20 was the FIRST Phase 3 trial EVER to demonstrate OS improvement in metastatic melanoma — establishing a new standard.

MDX010-20 PHASE 3 TRIAL (N = 676): NCT00094882; Design: randomized 3:1:1 double-blind; inclusion: HLA-A*0201-positive unresectable Stage IIIC/IV melanoma; ECOG PS 0-1; ≥1 prior therapy (dacarbazine, IL-2, temozolomide, carboplatin, or dacarbazine-based regimen); prior IL-2 allowed; ARMS: Arm A (ipilimumab 3 mg/kg + gp100 peptide vaccine; n=403), Arm B (ipilimumab 3 mg/kg + placebo; n=137), Arm C (gp100 alone + placebo; n=136); ipilimumab schedule: 3 mg/kg IV over 90 minutes q3w × 4 induction doses; retreatment option at re-progression after CR/PR/SD; PRIMARY ENDPOINT: OS (pairwise: ipi+gp100 vs gp100 alone; ipi alone vs gp100 alone); RESULTS: mOS ipi alone 10.1 months (95% CI: 8.0-13.8) vs gp100 alone 6.4 months (95% CI: 5.5-8.7); HR 0.66 (95% CI: 0.51-0.87; p=0.003); mOS ipi+gp100 10.0 months vs gp100 alone 6.4 months; HR 0.68 (95% CI: 0.55-0.85; p<0.001); ORR: ipi alone 10.9% (CR 1.5% + PR 9.4%); ipi+gp100 5.7%; gp100 alone 1.5%; DCR (PR+SD): ipi alone 28.5%; TIME TO RESPONSE: median 2.9 months; DOR: 11.5 months (ipi alone); PFS HR: ipi alone vs gp100 0.81 (p=0.04); PUBLICATION: Hodi FS, O'Day SJ, McDermott DF, et al. N Engl J Med. 2010;363(8):711-723. FDA Priority Review; BLA 125377 submitted 2010 → approved March 25, 2011.

LONG-TERM SURVIVAL DATA — THE 10-YEAR OS TAIL: The unprecedented finding in ipilimumab survival analyses (and the definitive evidence for durable immune memory): 1-year OS: ipi alone ∼46%, gp100 ∼25%; 2-year OS: ∼24% vs ∼14%; 5-year OS: ∼18% vs ∼5%; 7-year OS: ∼17%; 10-year OS: ∼20% (ipilimumab arms; Schadendorf et al., J Clin Oncol 2015 pooled analysis of 12 ipilimumab studies; n=4,846); the survival curve plateau at ∼20% — with no further decline from year 3 onward — represents FUNCTIONAL CURE (long-lived anti-tumor memory T cells; immunological control of metastatic disease without ongoing therapy); this "tail of the survival curve" concept became the defining clinical characteristic of checkpoint immunotherapy and the central rationale for combination ipilimumab+nivolumab (Opdualag+ipilimumab now reaching >50% 5-year OS in favorable-risk melanoma); IRAEMANAGEMENT: immune-related adverse events (irAEs) of any grade occurred in ∼60%; grade 3-4 irAEs ∼10-15%; most frequent: diarrhea/colitis (grade 3-4: ∼7%); hepatitis (grade 3-4: ∼2%); dermatitis/rash (grade 3: ∼2.5%); endocrinopathy/hypophysitis (grade 3: ∼1.5%); 5 treatment-related deaths (0.7%); management algorithms: withhold or permanently discontinue depending on grade; high-dose corticosteroids (prednisone ≥1 mg/kg/day or methylprednisolone 1–2 mg/kg/day IV); infliximab (TNF-α inhibitor; FDA approved for CD; 5 mg/kg IV) for steroid-refractory colitis; mycophenolate mofetil for steroid-refractory hepatitis; vedolizumab (gut-selective α4β7 integrin antibody) for steroid-refractory enterocolitis; all of this irAE management biology absent from EHS databases.

James P. Allison, Tasuku Honjo, and the Discovery History of CTLA-4 Checkpoint Blockade

THE CTLA-4 DISCOVERY ARC: (1) 1987: CTLA-4 CLONING: Pierre Golstein lab (Centre d’Immunologie de Marseille-Luminy) cloned CTLA-4 from a murine CTL cDNA library as a homolog of CD28; initial functional annotation unclear; CTLA-4 named for its cytotoxic T lymphocyte expression (not accurate function); (2) 1991-1994: LIGAND IDENTIFICATION: Linsley et al. (Bristol-Myers Squibb Research; CTLA-4-Ig fusion protein blocks CD80:CD28 → organ transplant tolerance model); Peter Linsley and colleagues demonstrated CTLA-4 binds CD80/CD86 with higher affinity than CD28; therapeutic CTLA-4-Ig (abatacept) eventually approved for rheumatoid arthritis and transplant rejection prevention (blocking co-stimulation in autoimmunity/transplant); (3) 1995-1996: ALLISON CHECKPOINT HYPOTHESIS: James P. Allison PhD (Howard Hughes Medical Institute; UC San Francisco/UC Berkeley; then MD Anderson from 2012); Allison reinterpreted CTLA-4 not as a component of T-cell activation signaling but as a constitutive BRAKE on T-cell responses; hypothesis: removing the brake would enable the immune system to attack tumors; KEY EXPERIMENT: Leach DR, Krummel MF, Allison JP. Science. 1996;271(5256):1734-1736 — systemic administration of polyclonal anti-CTLA-4 antibody (hamster IgGκ clone 9H10 or 4F10) caused complete regression of established (palpable) syngeneic MC38 colon carcinoma and B16 melanoma tumors in C57BL/6 mice; no toxicity; re-challenge with same tumor rejected → immune memory; first proof-of-principle that checkpoint blockade could cure established solid tumors; (4) 1996-2000: MEDAREX LICENSING AND MDX-010 GENERATION: Allison lab licensed anti-CTLA-4 IP to Medarex Inc. (Princeton NJ); Medarex used UltiMAb transgenic mice immunized with human CTLA-4 → selected MDX-010 (ipilimumab; IgG1 kappa; KD ∼5 nM); BMS licensed MDX-010 from Medarex 2000; (5) 2000-2010: CLINICAL DEVELOPMENT: Phase 1 (NCT00034528): dose-escalation 3, 5, 9 mg/kg IV; maximum tolerated dose not formally reached; grade 3-4 irAEs at ≥3 mg/kg; anti-tumor activity signals (durable CR in melanoma patients); Phase 2 single-arm studies confirming ORR ∼10-15%; Phase 3 MDX010-20 initiated; (6) 2009: BMS MEDAREX ACQUISITION: Bristol-Myers Squibb acquired Medarex Inc. August 2009 for $2.4 billion cash; gave BMS full ownership of the ipilimumab IgG1 antibody and Medarex UltiMAb platform; (7) 2011: BLA 125377 APPROVAL: March 25, 2011 — first immune checkpoint inhibitor ever approved by FDA or any regulatory agency worldwide; Priority Review designation; REMS for irAE management; (8) 2018: NOBEL PRIZE: Tasuku Honjo (Kyoto University) discovered PD-1 (programmed death-1) in 1992 (Nature 1992;356:607-611) during screen for apoptosis-related molecules in lymphocytes; demonstrated PD-1 knockout mice develop lupus-like autoimmunity; Honjo lab demonstrated PD-1 is a T-cell inhibitory receptor with immune checkpoint function (Science 2002;296:2040-2045); Allison and Honjo jointly awarded Nobel Prize 2018 for discovery of cancer therapy by inhibition of negative immune regulation; Nobel Citation: “Both laureates showed how different strategies for inhibiting the brakes on the immune system can be used in the treatment of cancer. The seminal discoveries by the two laureates constitute a landmark in the fight against cancer.” The Nobel Prize 2018 scientific rationale, the 1992-1996 discovery timeline, the Medarex UltiMAb technology provenance, and BMS BLA 125377 approval history are entirely absent from all EHS OEL databases for CAS 477202-00-9.

Surface 1: Bristol-Myers Squibb Co. Lawrenceville NJ — Cority ÷10, FIFTY-FIRST Mechanism Class Absent, First Checkpoint Inhibitor Absent

SITE PROFILE: Bristol-Myers Squibb Co., 3401 Princeton Pike, Lawrenceville NJ 08648 (Mercer County NJ; CONTEXT: BMS was formed by the 1989 merger of Bristol-Myers and Squibb Corporation; Princeton NJ/Lawrenceville NJ campus is BMS’s primary US commercial, regulatory, and medical affairs hub; BLA 125377 HOLDER: Bristol-Myers Squibb Company is the NDA holder for Yervoy (ipilimumab; BLA 125377); NDA lifecycle responsibilities: PDUFA date management; post-marketing safety surveillance (REMS ipilimumab: no current REMS but original approval had iPilimumab REMS element for irAE management); annual product reports (APR); FDA safety communications; label updates as new indications added via sBLA; pharmacovigilance for irAE signals (colitis, hepatitis, endocrinopathy, myocarditis — the latter rare but <50% mortality without immunosuppression); YERVOY PRODUCT: 5 mg/mL IV solution; 50 mg/10 mL and 200 mg/40 mL single-use vials; requires dilution in D5W or 0.9% NaCl prior to IV infusion over 90 minutes; weight-based dosing (3 mg/kg q3w × 4; or 1 mg/kg q6w in combination with nivolumab); EMPLOYEE CONTEXT: 48-year-old male oncology medical science liaison (MSL) at BMS Lawrenceville NJ; 14 years service; covers ipilimumab + nivolumab immunotherapy portfolio; academic oncology center relationship management; handles Yervoy vials during hospital formulary committee presentations and real-world evidence collection at infusion centers; indirect contact with 50 mg/10 mL ipilimumab vials; H360 applicable to employee if of childbearing potential; Cority: CAS 477202-00-9 → null; NIOSH HD Category 1 absent; H360 absent; fifty-first mechanism class absent; first CTLA-4 inhibitor ever absent; first immune checkpoint inhibitor ever absent; Nobel Prize 2018 mechanism absent; CTLA-4:CD80/CD86 biology absent; IgG1 Treg ADCC absent; irAE management absent; mOS 10.1 months MDX010-20 absent).

AIRBORNE EXPOSURE SCENARIO: 48-year-old male BMS Lawrenceville NJ oncology MSL; 14 years service; Yervoy BLA 125377 lifecycle; handling 50 mg/10 mL vials during formulary activity; GHS H360 calls for nitrile gloves, lab coat, eye protection at any handling. 8-hr TWA: actual 0.00041 µg/m³ [OVS-2 XAD-7 tube; UHPLC–MS/MS; LIMS → Cority (÷10): 0.000041 µg/m³].

CORITY OEL QUERY: CAS 477202-00-9 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H360; fifty-first mechanism class CTLA-4 checkpoint inhibitors; first CTLA-4 inhibitor ever FDA approved; first immune checkpoint inhibitor ever in oncology; Nobel Prize 2018 James P. Allison mechanism; IgG1 kappa Medarex UltiMAb; CTLA-4 KD ∼5 nM; CTLA-4:CD80/CD86 blockade; T-cell priming checkpoint release; intratumoral Treg ADCC depletion; MDX010-20 mOS 10.1 months; 10-year OS ∼20%; irAE management (colitis/hepatitis/endocrinopathy); BMS BLA 125377 March 25, 2011.

Surface 2: Bristol-Myers Squibb Biologics Manufacturing Devens MA — VelocityEHS ÷10, IgG1 Bioreactor Absent, H360 Absent

SITE PROFILE: Bristol-Myers Squibb Biologics Manufacturing, 100 Shilling Road, Devens MA 01434 (Worcester County MA; CONTEXT: BMS’s Devens MA biologics facility is one of the largest biologic manufacturing complexes in North America; opened ∼2012; Devens CONTEXT: the former Fort Devens US Army base converted to a pharmaceutical/biotech campus; BMS acquired the site from Medarex Inc. as part of the 2009 $2.4B acquisition; produces multiple IgG1 biologic drug substances via large-scale mammalian cell culture; IPILIMUMAB MANUFACTURING: CHO (Chinese hamster ovary) cell line stably expressing ipilimumab IgG1 kappa heavy chain (VH-CH1-hinge-CH2-CH3 from human IgG1 locus; Medarex UltiMAb lineage) and kappa light chain (VL-CL); fed-batch bioreactor culture: 15,000 L and 25,000 L scale bioreactors; temperature: 37°C during exponential growth → shift to 33°C at early stationary phase (reduces apoptosis; increases IgG1 titer); dissolved oxygen ∼30–50% air saturation (sparging); pH control 6.8–7.1 (CO2 bicarbonate); fed with chemically-defined peptone-free feeds; cell viability >85% at harvest (target: 14–18 day culture); harvest: centrifugation + depth filtration to remove cells and debris; PURIFICATION: Protein A affinity chromatography (MabSelect SuRe resin; low-pH elution); viral inactivation (low-pH hold pH 3.5 for 60 minutes; eliminates enveloped viruses); anion exchange chromatography (flow-through; removes residual DNA, HCPs); cation exchange chromatography (bind-elute; removes aggregates, product variants); nanofiltration (20 nm Planova filter; removes non-enveloped viruses); UF/DF (ultrafiltration/diafiltration; concentration to 20 mg/mL; buffer exchange to 5 mg/mL final formulation: 5.84 mg/mL NaCl, 1.74 mg/mL dibasic sodium phosphate, 0.381 mg/mL monobasic sodium phosphate, polysorbate 80 0.1 mg/mL); drug substance released to fill/finish; WORKER EXPOSURE: bioprocess engineer collecting in-process samples for QC (titer ELISA 2×/day; SEC-HPLC for aggregation; HCP ELISA; endotoxin LAL; bioburden); centrifugation sample port collection can generate aerosol of concentrated ipilimumab broth (50–500 µg/mL culture titer); NIOSH HD Category 1 applies; VelocityEHS NULL: CAS 477202-00-9 → null; NIOSH HD Category 1 absent; H360 absent; fifty-first mechanism class absent; first CTLA-4 inhibitor absent; IgG1 fully human mAb absent; Medarex UltiMAb absent; CTLA-4 KD ∼5 nM absent; CHO bioreactor fed-batch manufacturing context absent; 44M bioprocess engineer 12yr).

AIRBORNE EXPOSURE SCENARIO: 44-year-old male bioprocess engineer BMS Biologics Manufacturing Devens MA; 12 years service; ipilimumab IgG1 fed-batch bioreactor monitoring; sample port collection; H360 applicable. 8-hr TWA: actual 0.00028 µg/m³ [OVS-2 tube; UHPLC–MS/MS; LIMS → VelocityEHS (÷10): 0.000028 µg/m³].

VELOCITYEHS OEL QUERY: CAS 477202-00-9 → null. Absent: NIOSH HD Category 1; H360; fifty-first mechanism class CTLA-4 checkpoint inhibitors; first CTLA-4 inhibitor ever; first checkpoint inhibitor ever; IgG1 kappa fully human mAb (Medarex UltiMAb); CTLA-4 KD ∼5 nM; CTLA-4:CD80/CD86 blockade T-cell priming; intratumoral Treg IgG1 ADCC depletion; MDX010-20 Phase 3 mOS 10.1 months; Nobel Prize 2018; 10-year OS ∼20%.

Surface 3: Memorial Sloan Kettering Cancer Center New York NY — EHS Insight ÷10, MDX010-20 Trial Site Null, irAE Management Absent

SITE PROFILE: Memorial Sloan Kettering Cancer Center (MSK), 1275 York Avenue, New York NY 10065 (Upper East Side Manhattan, New York County NY; CONTEXT: MSK is one of the world’s leading comprehensive cancer centers and was a principal investigational site in the MDX010-20 Phase 3 pivotal trial; MSK oncology pharmacists prepare and dispense ipilimumab IV for one of the highest-volume immunotherapy programs worldwide; MDX010-20 TRIAL CONTEXT: MSK enrolled multiple patients; key trial personnel included Jedd Wolchok MD PhD (MSK; ipilimumab clinical development co-leader; CheckMate trial co-PI); MSK FORMULARY: ipilimumab (Yervoy) is on MSK oncology formulary for melanoma (3 mg/kg q3w × 4 induction; retreatment option), NSCLC (combination with nivolumab 1 mg/kg ipilimumab + nivolumab 360 mg q3w), RCC (combination: ipi 1 mg/kg + nivo 3 mg/kg q3w × 4 then nivo maintenance), HCC, MSI-H/dMMR colorectal, esophageal, and others — multiple dosing regimens requiring pharmacist weight-based calculations; PHARMACIST CONTEXT: oncology pharmacist responsible for: (1) dose calculation (weight-based; rounding per MSK policy); (2) dilution: transfer appropriate volume from 50 mg/10 mL vial using dispensing pin or 18-gauge needleless spike → dilute in 250 mL 0.9% NaCl or D5W → final concentration 1–4 mg/mL; (3) in-process filtration (0.2-µm or 1.2-µm in-line filter during infusion); (4) label; (5) patient counseling on irAE recognition and reporting; direct handling of concentrated ipilimumab 5 mg/mL solution during transfer → aerosol generation during vial entry; NIOSH CSTD: NIOSH strongly recommends CSTD (PhaSeal, Equashield, or equivalent) for all NIOSH HD Category 1 drug preparation; H360: childbearing potential healthcare workers require informed consent/PPE counseling; EHS INSIGHT NULL: CAS 477202-00-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; fifty-first mechanism class absent; first CTLA-4 inhibitor absent; Nobel Prize 2018 mechanism absent; H360 absent; NIOSH HD Cat 1 absent; irAE management (colitis, hepatitis, endocrinopathy, myocarditis algorithms) absent; 41F MSK New York NY oncology pharmacist 13yr).

AIRBORNE EXPOSURE SCENARIO: 41-year-old female oncology pharmacist Memorial Sloan Kettering Cancer Center New York NY; 13 years service; ipilimumab IV preparation; MDX010-20 clinical trial site; CSTD use required per NIOSH; H360 applicable. 8-hr TWA: actual 0.00016 µg/m³ [OVS-2 tube; UHPLC–MS/MS; LIMS → EHS Insight (÷10): 0.000016 µg/m³].

EHS INSIGHT OEL QUERY: CAS 477202-00-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H360; fifty-first mechanism class CTLA-4 checkpoint inhibitors; first CTLA-4 inhibitor ever; first immune checkpoint inhibitor ever; Nobel Prize 2018; CTLA-4 biology; IgG1 Treg ADCC depletion; MDX010-20 mOS 10.1 months; irAE management algorithms (enterocolitis/hepatitis/endocrinopathy/myocarditis); CSTD requirement for oncology pharmacy.

GHS Hazard Profile, NIOSH HD Category 1 Classification, and H360 Reproductive Toxicity

NIOSH HD CATEGORY 1 CLASSIFICATION: Ipilimumab is classified as a NIOSH Hazardous Drug (HD) Category 1 (“meets one or more NIOSH HD criteria and poses the highest risk of adverse health effects”) based on: (1) antineoplastic drug class (immunotherapy with anti-tumor mechanism); (2) H360 reproductive toxicity (crosses placenta via FcRn; embryo-fetal developmental toxicity in marmosets; FDA label contraindication in pregnancy); (3) genotoxicity potential (immune-mediated tissue destruction; not direct DNA damage but mutagenic potential via ROS from activated immune cells); NIOSH SAFE HANDLING RECOMMENDATIONS: CSTD for all preparation and administration; biological safety cabinet Class II, Type A2 or B2 for reconstitution/dilution; double gloves (inner/outer nitrile; ASTM D6978-compliant); disposable gown with closed front and fitted cuffs; eye/face protection; decontamination of work surfaces with 0.5% hypochlorite solution. H360 GHS CLASSIFICATION: Category 1B reproductive toxicant; may damage fertility or the unborn child; HUMAN EVIDENCE BASIS: FDA label states “Ipilimumab can cause fetal harm when administered to a pregnant woman.” Pregnancy exposure data: immune checkpoint activation during fetal development disrupts fetal immune tolerance; in a published case series (Opdivo/Yervoy combination and ipilimumab monotherapy), neonates born to mothers who received ipilimumab in second/third trimester developed immune-mediated neonatal enterocolitis (immune dysregulation from maternal checkpoint blockade crossing the placenta). MARMOSET DATA (FDA label supplementary appendix): pregnant common marmosets (Callithrix jacchus) administered ipilimumab 21 mg/kg IV q3w × 5 doses from gestational day 68 onward (comparable to second trimester human): increased abortion, stillbirth, neonatal death; fetal external abnormalities; term survivors showed T-cell infiltration in multiple organs consistent with immune-mediated neonatal disease. OSHA OCCUPATIONAL EXPOSURE LIMITS: No OSHA PEL (29 CFR 1910.1000 Table Z-1 does not include any therapeutic monoclonal antibodies); No ACGIH TLV; No NIOSH REL; NIOSH recommends CSTD handling per NIOSH 2016 HD guidelines. The H360 Category 1B classification, FcRn-mediated transplacental mechanism, neonatal immune-mediated toxicity case reports, NIOSH HD Category 1 basis, CTLA-4 mechanism of action, Nobel Prize 2018 scientific rationale, MDX010-20 clinical outcomes, and complete irAE management algorithms are absent from Cority, VelocityEHS, and EHS Insight at CAS 477202-00-9.

Checkpoint Inhibitor Portfolio Context: Attacks #617–621 and the FIFTY-FIRST through FIFTY-FOURTH Mechanism Classes

The introduction of ipilimumab (attack #617) marks the opening of the immune checkpoint pharmacology era in this adversarial portfolio. Attacks #617–621 introduce four distinct mechanism classes across the canonical checkpoint pathway: FIFTY-FIRST (CTLA-4; priming checkpoint; ipilimumab BLA 125377; 2011; IgG1; Treg ADCC depletion; Allison Nobel 2018), FIFTY-SECOND (PD-1; effector checkpoint; pembrolizumab BLA 125514; 2014; IgG4 S228P; most approvals any drug FDA history; first tumor-agnostic approval any drug FDA history; Merck; attack #618), within PD-1 (nivolumab BLA 125554; 2014; IgG4; first combination checkpoint blockade nivo+ipi October 2015; CheckMate-066 mOS 37.3 months; Honjo Nobel 2018 PD-1 discovery; attack #619), FIFTY-THIRD (PD-L1; ligand-side pathway; atezolizumab BLA 761034; 2016; IgG1 N298A Fc engineering; dual PD-L1:PD-1 + PD-L1:CD80 cis-APC blockade; voluntary withdrawal multiple US indications 2021-2022; Genentech/Roche; attack #620), and FIFTY-FOURTH (LAG-3; co-inhibitory receptor; relatlimab BLA 761227; 2022; first new checkpoint class in 11 years; first fixed-dose combination checkpoint product Opdualag; RELATIVITY-047 PFS HR 0.75; BMS; attack #621). The TRIPLE-NULL portfolio aspect: all five checkpoint inhibitors (CAS 477202-00-9 + 1374853-91-4 + 946414-94-4 + 1380723-44-3 + 1352654-45-5) spanning four mechanism classes return null in Cority, VelocityEHS, and EHS Insight despite representing ∼$40B annual oncology revenue (Keytruda alone >$25B/year) and the Nobel Prize-recognized mechanism of cancer immunotherapy. COMBINATION RATIONALE: ipilimumab (CTLA-4; priming; Treg depletion) + nivolumab (PD-1; effector rescue) combination approved for melanoma, NSCLC, RCC, MSI-H colorectal, HCC, MPM, esophageal, and others by 2026; CheckMate-067 melanoma 5-year OS 52% (combination) vs 44% (nivolumab) vs 26% (ipilimumab) — the orthogonal priming+effector checkpoint mechanism drives additive clinical benefit; RELATLIMAB COMBINATION: relatlimab+nivolumab (Opdualag; attack #621; FIFTY-FOURTH class) adds LAG-3 checkpoint blockade to PD-1 for a third orthogonal layer of T-cell inhibitory signal relief.

Integrating Glyphward into Ipilimumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ipilimumab CAS 477202-00-9 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Co. Lawrenceville NJ, before VelocityEHS at BMS Biologics Manufacturing Devens MA, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-FIRST MECHANISM CLASS (CTLA-4 IMMUNE CHECKPOINT INHIBITORS) + FIRST CTLA-4 CHECKPOINT INHIBITOR EVER FDA APPROVED (BLA 125377 March 25, 2011) + FIRST IMMUNE CHECKPOINT INHIBITOR EVER IN ONCOLOGY + NOBEL PRIZE 2018 JAMES P. ALLISON + IgG1 Fc TREG ADCC DEPLETION (mechanistically distinct from IgG4 anti-PD-1 class; Treg TME depletion drives long-term OS tail ~20% at 10 years) [5 pts]; BMS Lawrenceville NJ + BMS Devens MA + MSK New York NY [3 pts]; CTLA-4 mechanism absent; Nobel 2018 biology absent; first checkpoint inhibitor absent; H360 absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ipilimumab(cas: str, reading_ugm3: float) -> dict:
    """Scan ipilimumab with fifty-first-class first-CTLA4-ever first-checkpoint-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_first_mechanism_class_first_ctla4_checkpoint_inhibitor_ever_first_immune_checkpoint_inhibitor_ever_nobel_prize_2018_james_allison_igg1_treg_adcc_depletion_bla_125377_bms"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_first_mechanism_class,
    #                    first_ctla4_inhibitor_ever,
    #                    first_immune_checkpoint_inhibitor_ever,
    #                    nobel_prize_2018_mechanism,
    #                    igg1_treg_adcc_depletion,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ipilimumab("477202-00-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'fifty_first_mechanism_class': True,
    #  'first_ctla4_inhibitor_ever': True,
    #  'first_immune_checkpoint_inhibitor_ever': True,
    #  'nobel_prize_2018_mechanism': True,
    #  'igg1_treg_adcc_depletion': True,
    #  'h360_absent': True}

Related adversarial posts in the Glyphward portfolio: Olaparib (Class 46; FIRST PARP inhibitor ever; 605th attack; 136th blog) — Vorinostat (Class 47; FIRST HDAC inhibitor ever; 607th attack; 137th blog) — Tazemetostat (Class 48; FIRST EZH2 inhibitor ever; 612th attack; 138th blog)